Venmax Drugs & Pharmaceuticals Intrinsic Value
Venmax Drugs & Pharmaceuticals (VENMAX) median intrinsic value is ₹23.33 from 2 valuation models (range ₹7–₹23), vs current price ₹23.96 — -2.6% downside (Trading Near Calculated Value), margin of safety -2.7%. Also explore VENMAX share price history to track price trends across different timeframes.
VENMAX Valuation Methods Summary — DCF, Graham Number & P/E
Venmax Drugs & Pharmaceuticals intrinsic value across 2 models vs current price ₹23.96 — upside/downside and value range per method. For current market price and key ratios, visit VENMAX screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹23.33 | ₹21.00 - ₹25.66 | -2.6% | Book Value/Share: ₹11.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹7.19 | ₹6.47 - ₹7.91 | -70.0% | Revenue/Share: ₹1.67, P/S: 2.0x |
VENMAX Intrinsic Value vs Market Price — All Valuation Models
Venmax Drugs & Pharmaceuticals fair value range ₹7–₹23 vs current market price ₹23.96 across 2 valuation models. Browse Venmax Drugs & Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
VENMAX Intrinsic Value Analysis — Undervalued or Overvalued?
Venmax Drugs & Pharmaceuticals median intrinsic value ₹23.33, current price ₹23.96 — Trading Near Calculated Value by 2.6%, margin of safety -2.7%.
What is the intrinsic value of VENMAX?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Venmax Drugs & Pharmaceuticals (VENMAX) is ₹23.33 (median value). With the current market price of ₹23.96, this represents a -2.6% variance from our estimated fair value.
The valuation range spans from ₹7.19 to ₹23.33, indicating ₹7.19 - ₹23.33.
Is VENMAX undervalued or overvalued?
Based on our multi-method analysis, Venmax Drugs & Pharmaceuticals (VENMAX) appears to be trading near calculated value by approximately 2.6%.
VENMAX Financial Health — Key Ratios vs Industry Benchmarks
Venmax Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | -131.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.12x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VENMAX Cash Flow Quality — Operating & Free Cash Flow
Venmax Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |